Literature DB >> 7783638

Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus.

J C Milne1, S R Blanke, P C Hanna, R J Collier.   

Abstract

The edema factor (EF) and lethal factor (LF) components of anthrax toxin require anthrax protective antigen (PA) for binding and entry into mammalian cells. After internalization by receptor-mediated endocytosis, PA facilitates the translocation of EF and LF across the membrane of an acidic intracellular compartment. To characterize the translocation process, we generated chimeric proteins composed of the PA recognition domain of LF (LFN; residues 1-255) fused to either the amino-terminus or the carboxy-terminus of the catalytic chain of diphtheria toxin (DTA). The purified fusion proteins retained ADP-ribosyltransferase activity and reacted with antisera against LF and diphtheria toxin. Both fusion proteins strongly inhibited protein synthesis in CHO-K1 cells in the presence of PA, but not in its absence, and they showed similar levels of activity. This activity could be inhibited by adding LF or the LFN fragment (which blocked the interaction of the fusion proteins with PA), by adding inhibitors of endosome acidification known to block entry of EF and LF into cells, or by introducing mutations that attenuated the ADP-ribosylation activity of the DTA moiety. The results demonstrate that LFN fused to either the amino-terminus or the carboxy-terminus of a heterologous protein retains its ability to complement PA in mediating translocation of the protein to the cytoplasm. Besides its importance in understanding translocation, this finding provides the basis for constructing a translocation vector that mediates entry of a variety of heterologous proteins, which may require a free amino- or carboxy-terminus for biological activity, into the cytoplasm of mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7783638     DOI: 10.1111/j.1365-2958.1995.tb02375.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  83 in total

1.  Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N-end-rule pathway.

Authors:  P O Falnes; R Welker; H G Kräusslich; S Olsnes
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

2.  Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin.

Authors:  J Mogridge; M Mourez; R J Collier
Journal:  J Bacteriol       Date:  2001-03       Impact factor: 3.490

3.  Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity.

Authors:  Y Lu; R Friedman; N Kushner; A Doling; L Thomas; N Touzjian; M Starnbach; J Lieberman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

4.  Mutational analysis of the enzymatic domain of Clostridium difficile toxin B reveals novel inhibitors of the wild-type toxin.

Authors:  Lea M Spyres; Jeremy Daniel; Amy Hensley; Maen Qa'Dan; William Ortiz-Leduc; Jimmy D Ballard
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

5.  Evidence that translocation of anthrax toxin's lethal factor is initiated by entry of its N terminus into the protective antigen channel.

Authors:  Sen Zhang; Alan Finkelstein; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-17       Impact factor: 11.205

Review 6.  Ratcheting up protein translocation with anthrax toxin.

Authors:  Geoffrey K Feld; Michael J Brown; Bryan A Krantz
Journal:  Protein Sci       Date:  2012-03-30       Impact factor: 6.725

7.  Structural basis for the unfolding of anthrax lethal factor by protective antigen oligomers.

Authors:  Geoffrey K Feld; Katie L Thoren; Alexander F Kintzer; Harry J Sterling; Iok I Tang; Shoshana G Greenberg; Evan R Williams; Bryan A Krantz
Journal:  Nat Struct Mol Biol       Date:  2010-10-31       Impact factor: 15.369

8.  Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.

Authors:  T J Goletz; K R Klimpel; N Arora; S H Leppla; J M Keith; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

9.  Receptor-specific requirements for anthrax toxin delivery into cells.

Authors:  G Jonah A Rainey; Darran J Wigelsworth; Patricia L Ryan; Heather M Scobie; R John Collier; John A T Young
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-01       Impact factor: 11.205

10.  Inhibition of anthrax protective antigen outside and inside the cell.

Authors:  Marina V Backer; Vimal Patel; Brian T Jehning; Kevin P Claffey; Vladimir A Karginov; Joseph M Backer
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.